| Document |
Document Title |
|
WO/2023/068325A1 |
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nit...
|
|
WO/2023/067485A1 |
Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical compositio...
|
|
WO/2023/067483A1 |
The invention relates to a pharmaceutical combination comprising an MDM2 inhibitor, a BCL2 inhibitor and a hypomethylating agent. The present invention also relates to methods of treating haematological malignancies involving said combin...
|
|
WO/2023/068176A1 |
Provided are: a neuron proliferation promoting agent containing, as an active ingredient, an inhibitor of miR-191-5p or an expression inhibitor of miR-191-5p; a prophylactic or therapeutic agent for Alzheimer's disease or depression, the...
|
|
WO/2023/069037A1 |
The present invention relates to ophthalmic formulations for the treatment of presbyopia, dry eye disease and computer vision syndrome, and a method for preparing the same. The objective of the present invention is to treat symptoms caus...
|
|
WO/2023/068366A1 |
The present invention addresses mainly the problem of providing a novel composition or pharmaceutical that targets the mitochondrial network etc. and exhibits excellent anticancer activity while having a minimal effect on normal cells.ã€...
|
|
WO/2023/068226A1 |
The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said an...
|
|
WO/2023/067501A1 |
In one aspect, methods are provided for treating a human subject having or susceptible to mucositis, comprising administering to the human subject an effective amount of EC-18, thereby treating or preventing the mucositis.
|
|
WO/2023/065551A1 |
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic co...
|
|
WO/2023/061446A1 |
The present invention belongs to the field of medicine. Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and a PPARα agonist, w...
|
|
WO/2023/063154A1 |
[Problem] To provide: a novel tracer drug for radioactive PET diagnosis that has high accumulation properties and retention properties at a tumor site, and an efficient production method (labeling synthesis method) of the tracer drug. [S...
|
|
WO/2023/063827A1 |
The invention relates to a bismuth containing composition for use in prophylaxis or treatment of an infection by Pseudomonas (P.) aeruginosa. The invention further relates to the concomitant use of a bismuth containing compound and an an...
|
|
WO/2023/063026A1 |
A problem addressed by the present invention is to provide an anti-MerTK antibody that has a tumor-suppressing effect and does not tend to cause ocular toxicity.　The present invention provides an antibody or a fragment thereof that bin...
|
|
WO/2023/062149A1 |
The present invention concerns a new method based on the combination of a particular osmotic swelling, an adapted and controlled plasma membrane lysis and removal, to produce said giant extracellular organelles vesicles, and use of said ...
|
|
WO/2023/063325A1 |
The purpose of the present invention is to provide therapeutic and preventive agents for COVID-19. The present invention provides a therapeutic or preventive composition for COVID-19, said composition containing an ADAM10 inhibitor. The ...
|
|
WO/2023/061457A1 |
Disclosed in the present invention are an antibody-drug conjugate, a pharmaceutical composition comprising the antibody-drug conjugate, and an application of the antibody-drug conjugate and the pharmaceutical composition in preparation o...
|
|
WO/2023/063400A1 |
Provided is a transgenic non-human animal enabling an analysis of an evaluation of proteasome function and activity on an individual basis. The present invention relates to a transgenic non-human animal and the like with an attenuated pr...
|
|
WO/2023/020212A9 |
Use of a DRD2 inhibitor in the preparation of a drug for treating diseases associated with liver fibrosis. In one embodiment, the DRD2 inhibitor is Fluphenazine (Flu) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/063784A1 |
The present invention relates to a composition for combination therapy, comprising a 2,3,5-substituted thiophene compound, has an activity of inhibiting cancer cells associated with leukemia that is superior to that of treatment individu...
|
|
WO/2023/062222A1 |
The present invention relates to an association of a Faecalibacterium prausnitzii bacterial strain deposited to the CNCM under the accession number I-4573; and at least one immune checkpoint inhibitor, in particular at least one monoclon...
|
|
WO/2023/061554A1 |
The present invention relates to the use of 5-Hydroxymethylfurfural (5-HMF) for prevention and/or treatment of conditions or diseases, respectively, associated with mitochondrial dysfunction as well as corresponding treatment methods.
|
|
WO/2023/062159A1 |
The present invention relates to the association of at least one bacterial strain of the species Enterococcus faecalis and an anti-inflammatory agent, a composition comprising same, and the uses thereof as a medicament, in particular for...
|
|
WO/2023/064847A1 |
Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduc...
|
|
WO/2023/064819A1 |
Provided herein are methods of treating a subject having epidermolysis bullosa, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amniotic fluid substantially free of en...
|
|
WO/2023/062516A1 |
Preparations and forms of 2-deoxy-D-glucose (2-DG) for use in the treatment or prevention of a viral disease, collaboratively in the treatment of cancer with other cancer treatments, and in a natural preparation with natural minerals to ...
|
|
WO/2023/062354A2 |
The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and na...
|
|
WO/2023/057613A1 |
The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.
|
|
WO/2023/057386A1 |
The present application relates to compositions comprising sialic acid and/or fucose to enhance cognitive function by promoting differentiation of oligodendrocyte precursor cells into mature, myelinating oligodendrocytes.
|
|
WO/2023/059728A1 |
The present invention concerns methods of treating and/or preventing sexual dysfunction, wherein the sexual dysfunction is associated with one or more mental health conditions, the method using a pharmaceutical composition comprising the...
|
|
WO/2023/060227A1 |
The present invention provides methods for selecting a cancer patient who is YAP1 and/or TAZ nuclear positive, and methods for treating cancer in a cancer patient who is YAP1 and/or TAZ nuclear positive, and administering to the patient ...
|
|
WO/2023/058987A1 |
The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combina...
|
|
WO/2023/057819A1 |
The disclosure is in part directed to a method of treating a cancer in a patient in need thereof, comprising administering to the patient an effective amount of a HSF1 pathway inhibitor, wherein the cancer comprises solid tumors identifi...
|
|
WO/2023/057882A1 |
This disclosure relates to a method for treating cancer by administering a compound of Formula (I) in combination with a PD-1 axis binding antagonist to a subject in need thereof.
|
|
WO/2023/059703A1 |
Provided are methods for treating various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, ...
|
|
WO/2023/057879A1 |
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior...
|
|
WO/2023/057109A1 |
The present invention relates to the medical-pharmaceutical field of therapy of inflammatory diseases of in particular the human ear and more particularly of various forms of otitis such as otitis media. The invention particularly relate...
|
|
WO/2023/059148A1 |
The present invention relates to use of 2-chloro-N,N-diethylethylamine hydrochloride for improving anti-cancer treatment, and has the benefits of killing cancer cells by alkylating a DNA base using a nitrogen mustard-based compound of ch...
|
|
WO/2023/056972A1 |
Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of th...
|
|
WO/2023/056897A1 |
Provided is the use of a c-Abl inhibitor in the preparation of a drug for preventing and/or treating amyotrophic lateralizing sclerosis. Provided are the use of a c-Abl protein as a target in screening a drug for preventing and/or treati...
|
|
WO/2023/060094A1 |
Provided herein are compositions and methods of modulating an aversive taste of active pharmaceutical ingredients (API) in a medicament, nutrient, and/or a dietary supplement via inhibition of a purinergic receptor. Additionally provided...
|
|
WO/2023/051923A1 |
The present invention relates to a condensation product, obtained by the reaction of a phenolic compound and a carbonyl compound, or a pharmaceutical composition comprising the same for use in a method for the prevention or treatment of ...
|
|
WO/2023/050297A1 |
A topical pharmaceutical composition, comprising a blood volume expander, a non-synergistic drug, and a proper amount of solvent. The pharmacological concentration of the expander is less than or equal to 30%, preferably 2-30%, and more ...
|
|
WO/2023/054704A1 |
The present invention addresses the problem of providing technology for dispersing a water-soluble compound in oil that can be applied to pharmaceuticals.　The present invention provides a method for producing a lecithin-water-soluble c...
|
|
WO/2023/054706A1 |
The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and...
|
|
WO/2023/052520A1 |
The present invention relates to a condensation product, obtained or obtainable by reaction of phenol, formaldehyde, sulfuric acid and urea, for use in a method for the treatment or prevention of a condition associated with one or more p...
|
|
WO/2023/056433A1 |
Provided herein are compositions comprising a composite of peptide amphiphile nanofibers and hyaluronic acid (HA) particles, and methods of preparation and use thereof, such as for repair of a cartilage or osteochondral defects.
|
|
WO/2023/054423A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/051925A1 |
The present invention relates to a condensation product, obtained by the reaction of a phenolic compound and a carbonyl compound, for use in a method for the treatment or prevention of a condition associated with one or more protease(s) ...
|
|
WO/2023/055904A1 |
Compounds capable of binding to and inhibiting the activity of RAS protein are described herein along with compositions and methods useful for treating RAS protein related diseases such as, for example, cancer.
|
|
WO/2023/054578A1 |
The present invention pertains to a pharmaceutical composition for the prevention or treatment of respiratory diseases, particularly, inflammatory respiratory diseases, the pharmaceutical composition containing, as an active ingredient, ...
|
